Literature DB >> 327229

Serum reactions. An analysis of commercial antivenoms and the possible role of anticomplementary activity in de-novo reactions to antivenoms and antitoxins.

S K Sutherland.   

Abstract

Infusion of concentrated heterologous serum proteins may precipitate severe reactions in humans. Some of these reactions are not due to a preexisting hypersensitivity to the foreign protein, but rather to the strongly anticomplementary activity (ACA) of the infused protein. The latter mechanism could account for the occasional anaphylactoid reaction seen in a patient who has had no known previous exposure to the foreign protein. Similarly, it could account for the patient who fails to react to a preliminary subcutaneous trial dose, but then collapses when he is infused later with the same preparation. Nine commercial antivenoms from nine countries were examined and most were found to have high levels of anticomplementary activity. Considerable variation was found in both the immunochemical properties and the anticomplementary activity of these antivenoms. Antitoxins of equine origin to the toxins of diphtheria, tetanus and gas gangrene were also found to have high anticomplementary activity. Because of this activity these preparations should always be diluted and infused slowly. Lack of reaction to a test dose will never guarantee an uneventful infusion, and thus all infusions of heterologous immunoglobulin should be undertaken with the greatest caution and vigilance.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 327229

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  15 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Adverse reactions to snake antivenom, and their prevention and treatment.

Authors:  H Asita de Silva; Nicole M Ryan; H Janaka de Silva
Journal:  Br J Clin Pharmacol       Date:  2015-09-16       Impact factor: 4.335

3.  Snakes and snake bite.

Authors:  D A Warrell
Journal:  Br Med J       Date:  1978-07-29

Review 4.  Interventions for preventing reactions to snake antivenom.

Authors:  I Nuchpraryoon; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Study on development of Vipera lebetina snake anti-venom in chicken egg yolk for passive immunization.

Authors:  Hossein Zolfagharian; Naser Mohammadpour Dounighi
Journal:  Hum Vaccin Immunother       Date:  2015-02-20       Impact factor: 3.452

Review 6.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 7.  Immunotherapy in the poisoned patient. Overview of present applications and future trends.

Authors:  J B Sullivan
Journal:  Med Toxicol       Date:  1986 Jan-Feb

8.  Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus).

Authors:  D A Warrell; M J Warrell; W Edgar; C R Prentice; J Mathison; J Mathison
Journal:  Br Med J       Date:  1980-03-01

9.  Neutralization of two North American coral snake venoms with United States and Mexican antivenoms.

Authors:  Elda E Sánchez; Juan C Lopez-Johnston; Alexis Rodríguez-Acosta; John C Pérez
Journal:  Toxicon       Date:  2007-10-13       Impact factor: 3.033

10.  Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial.

Authors:  H Asita de Silva; Arunasalam Pathmeswaran; Channa D Ranasinha; Shaluka Jayamanne; Senarath B Samarakoon; Ariyasena Hittharage; Ranjith Kalupahana; G Asoka Ratnatilaka; Wimalasiri Uluwatthage; Jeffrey K Aronson; Jane M Armitage; David G Lalloo; H Janaka de Silva
Journal:  PLoS Med       Date:  2011-05-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.